Lexaria received independent review board approval for its HYPER-H21-4 human clinical study for hypertension treatment The stage is also set for other R&D programs for the 2022 calendar year, including HOR-A22-1, DEM-A22-1, RHEUM-A22-1 and DIAB-A22-1 All of these 2022 R&D programs are fully funded, with Lexaria having raised approximately $15 million over the 2021 calendar […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.